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Robust RNA-based in situ mutation detection
delineates colorectal cancer subclonal evolution
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Intra-tumor heterogeneity (ITH) is a major underlying cause of therapy resistance and dis-
ease recurrence, and is a read-out of tumor growth. Current genetic ITH analysis methods do
not preserve spatial context and may not detect rare subclones. Here, we address these
shortfalls by developing and validating BaseScope—a novel mutation-speciﬁc RNA in situ
hybridization assay. We target common point mutations in the BRAF, KRAS and PIK3CA
oncogenes in archival colorectal cancer samples to precisely map the spatial and morpho-
logical context of mutant subclones. Computational modeling suggests that subclones must
arise sufﬁciently early, or carry a considerable ﬁtness advantage, to form large or spatially
disparate subclones. Examples of putative treatment-resistant cells isolated in small topo-
graphical areas are observed. The BaseScope assay represents a signiﬁcant technical advance
for in situ mutation detection that provides new insight into tumor evolution, and could have
ramiﬁcations for selecting patients for treatment.
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Recent years have seen numerous studies reveal intra-tumorheterogeneity (ITH) as a major underlying cause of therapyresistance and cancer recurrence1, 2. At the genetic level,
ITH is most frequently measured by ‘bulk’ sequencing of tumor
biopsies3, or by single cell sequencing (a limited number of)
individual cells sorted by ﬂow cytometry4. However, these
approaches may fail to identify rare, potentially clinically relevant
subclones if they are present at a frequency below the limit of next
generation sequencing (NGS) detection or if they are incorrectly
classiﬁed as artefacts. A further limitation of these approaches is
that they do not preserve the tissue architecture; therefore the
spatial and histopathological context of tumor subclones is lost.
This information contains crucial clues as to the mechanisms of
subclone emergence, and thus can provide valuable and otherwise
inaccessible insight into tumor evolution.
In situ mutation detection (ISMD) is therefore a useful tool for
the study of tumor evolution and heterogeneity that preserves
spatial context. It may also be utilized to complement NGS data,
for example to conﬁrm the presence of low frequency variants, or
in the case of mRNA-ISMD to conﬁrm that a mutant transcript is
indeed expressed. Furthermore it could be applied diagnostically
as a tool for cost-effective and high-throughput screening of
samples of unknown mutational status, perhaps with the goal of
directing therapeutics. Existing ISMD techniques are, however,
limited by their technical complexity, and their lack of sensitivity
and/or speciﬁcity (see Discussion), and therefore have not been
widely adopted by researchers or in clinical practice. Here we
describe in situ analysis of mutational status at a cellular level
using novel BaseScope technology. The BaseScope assay is an
RNA in situ hybridization (ISH) technique, based on the same
principles as the well-established RNAscope mRNA expression
assay5, involving a unique probe design and signal ampliﬁcation
strategy. The technology utilizes ‘Z’ probes, each of which con-
tains an 18- to 25-base region complementary to the RNA
sequence of interest, followed by a spacer sequence, then a short
“tail” sequence that is recognized by the signal ampliﬁcation
system. The key concept in this technology is that signal ampli-
ﬁcation requires two ‘Z’ probes binding adjacent to each other in
order for a signal-generating “tree” to form at the target site. We
have shown this approach to be a highly sensitive and speciﬁc
approach to analysis of mRNA expression6, 7. Compared to
RNAscope, BaseScope incorporates an additional signal ampliﬁ-
cation step to further boost detection sensitivity without
increasing background noise. As a result, BaseScope requires only
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Fig. 1 Validation of BaseScope probes in cell lines. a Schematic of BaseScope technology. Binding of two custom-designed ‘Z’ probes to target mRNA
directs binding of a signal ampliﬁcation tree, allowing visualization of point mutations by FastRed. b, c Representative images of the validation of the KRAS
G12V probeset b and BRAF V600E probeset c In both cases a wild-type cell line and a homozygous mutant cell line are shown, with a negative control
probe (dapB), a positive control probe (POLR2A), the wild-type probe and the mutant probe. Probe binding is visualized as punctate red dots. Scale bars
represent 50 micron and 10 micron (inset)
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a single ZZ pair (‘1ZZ’) instead of the standard 20 ZZ pairs used
in RNAscope, allowing detection of short RNA sequences and the
discrimination between single nucleotide alterations (Fig. 1a).
Here, we demonstrate the sensitivity and speciﬁcity of custom-
designed, mutation-speciﬁc 1ZZ BaseScope probes for RNA-
based ISMD in cell lines and primary tumors.
We study the expansion of mutant subclones in colorectal
cancer (CRC). CRCs have a strong stereotypical histological
structure—they consist of thousands of individual glands, each
containing a few thousand cells that are thought to be recently
clonally derived from a smaller number of long-lived lineages
within the gland8–11. Previously, we have identiﬁed spatially-
contiguous subclonal expansions of glands within colorectal
adenomas using putatively neutral mitochondrial enzyme defects
to trace clones8, 12. The inter-gland clonal architecture of CRCs is
less well resolved: gland-by-gland measurement of methylation
patterns provided gross-scale spatial maps of clonal ancestry,
which mathematical modeling predicted were consistent with a
rapid initial burst of tumor growth followed by relative quies-
cence13. Subsequently, genome-wide copy-number analysis on a
gland-by-gland level revealed occasional extensive clonal mixing
within CRCs9, and a targeted DNA copy number analysis sug-
gested a complex 3D tumor architecture in a single extensively
mapped case14. Because these previous genotyping methods have
required laborious tissue microdissection, detailed topographical
maps of clone spread throughout CRCs are lacking.
Here we validate BaseScope ISMD technology and use it to map
the topography of subclones bearing driver mutations in one of the
KRAS, PIK3CA or BRAF proto-oncogenes in CRCs and adenomas.
Results
Validation of 1ZZ BaseScope probes in human cell lines. We
characterized a total of 9 probe sets designed to target driver gene
point mutations commonly found across human cancers: KRAS
(G12D, G12V, G12A, G12S, G12R, and G12C), BRAF (V600E)
and PIK3CA (E545K and H1047R, for probe details see Supple-
mentary Table 1). Validation was performed in well-characterized
human cell lines known to be mutant or wild-type for the
mutation of interest (Supplementary Table 2). All assays included
probes targeting the mutant sequence and the corresponding
wild-type sequence, together with positive and negative RNA
quality controls (negative control: bacterial mRNA dapB, positive
control: housekeeping gene POLR2A). BaseScope signals were
readily distinguishable as punctate red dots within cells (Fig. 1).
For each probe in each cell line, the proportion of cells containing
positive signal was quantiﬁed, with an average of 383 (±27) cells
counted per slide.
Firstly we validated the sensitivity and speciﬁcity of the 1ZZ
BaseScope technology by quantifying the staining of the positive
and negative control probes (Fig. 1, Supplementary Fig. 1 and
Supplementary Table 2). Across the cell lines examined (n =
16 slides representing 11 cell lines), an average of 99.1% (±0.4%)
of cells showed signal for the positive control probe (POLR2A)
whereas an average of 0.29% (± 0.20%) of cells displayed signal
for the negative control probe (dapB) indicating high sensitivity
and speciﬁcity, respectively.
To test the sensitivity of the mutation-speciﬁc 1ZZ BaseScope
probes, we applied them to the cell lines of known mutational
status (Fig. 1, Supplementary Fig. 1 and Supplementary Table 2).
In homozygous mutant cell lines (n = 4), an average of 85.6% (±
11.6) of cells were positive for expression of the mutation, and in
heterozygous mutant cell lines (n = 5), an average of 50.5% (±
16.9) of cells were positive. We note that there is likely natural
(biological) variation in gene expression meaning that not all cells
necessarily express the mutant transcript at detectable levels,
despite carrying the mutant gene. Technical repeats on three cell
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Fig. 2 Validation of BaseScope probes in tumors. Representative images of the validation of the KRAS G12D probeset a and BRAF V600E probeset b in
archival human tumor tissue. In both cases a wild-type tumor and a mutant tumor are shown, with a negative control probe (dapB), a positive control probe
(POLR2A), the wild-type probe and the mutant probe. Scale bars represent 50 micron and 10 micron (inset)
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lines, carried out at least 3 months apart, showed that this signal
was highly reproducible (no signiﬁcant difference in signal
quantiﬁcation between experimental repeats by the Mann-
Whitney test; n = 3 cell lines, Supplementary Fig. 2a). We then
tested the speciﬁcity of the mutation-speciﬁc BaseScope probes by
looking for positive signal in cell lines known to be wild-type for
the probe-speciﬁc mutation. Across the 9 probe sets, a non-
speciﬁc (putatively false positive) signal was observed in 0.08%
(± 0.08%) of cells. Finally, the homozygous mutant cell lines (n =
4) were used to determine the speciﬁcity of the wild-type
BaseScope probes, and an average non-speciﬁc ‘false positive’
signal was observed in 0.19% (± 0.27%) of cells.
Validation of 1ZZ BaseScope probes in human tumors. We
next evaluated the efﬁcacy of the BaseScope technology in
archival human tumors of known mutation status (Supplemen-
tary Tables 3 and 4). The negative control probe performed
similarly to the cell lines: non-speciﬁc signal (dapB) was detected
in 0.18% (± 0.21%) of cells (n = 5 representative tumors). How-
ever the fraction of cells positive for the positive control
(POLR2A) was variable between tumors, with an average of 66.0%
(± 24.8%) of cells (n = 4 representative tumors) displaying posi-
tive signal (Fig. 2 and Supplementary Table 4). This is likely
because of varying degrees of mRNA degradation that may occur
during processing and storage of FFPE material, together with
potential inter-tumor heterogeneity in POLR2A mRNA
expression.
Staining for mutation-speciﬁc BaseScope probes was entirely
consistent with prior knowledge of the mutational status of the
tumors (Fig. 2 and Supplementary Table 3). The proportion of
mutation-positive tumor cells in mutant samples was variable
with an average of 24.5% (± 12.5%; n = 4 tumors) whereas
reassuringly the proportion of mutant signal detected in wild-type
samples was very low at 0.15% (± 0.29%, n = 3 tumors). The
positive cell fraction was highly reproducible between technical
repeats (Supplementary Fig 2a). The tumor-stroma interface
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Fig. 3 BaseScope detection of CRC subclonal architecture. a Representative images showing BaseScope detection of a small patch of mutant cells (red)
within a ﬁeld of wild-type cells (yellow). Scale bars represent 200 micron. b Representative topographical maps of subclonal architecture showing the
spatial arrangement of mutant (red) and wild-type (yellow) subclones. Examples of low mixing (left column), intermediate mixing (middle column) and
high mixing (right column) are shown. Scale bars represent 2000 micron
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provided another demonstration of probe speciﬁcity: for example,
in a KRAS G12D homozygous mutant tumor, positive signal from
the KRAS wild-type probe was only evident in stromal cells
(Supplementary Fig. 2b).
We next sought to determine if BaseScope probes were also
effective in mutational screening of samples of uncertain
mutational status by using a pool of probes against the KRAS
mutations G12D, G12V, G12A, G12C, and G12R. We performed
pooled BaseScope staining on 21 colorectal adenomas containing
foci of cancer (‘Ca-in-ad’ tumors, see Methods and Supplemen-
tary Table 3) which all appeared KRAS wild-type by Sanger
sequencing from ‘bulk’ DNA. The pooled probes detected KRAS
mutations at subclonal frequency (for details see subsequent
Results sections) in 3/18 samples, and we then assayed these
samples with the individual probes to determine which speciﬁc
mutation was present. Importantly, we found the probes to be
highly speciﬁc to the individual mutation, displaying no cross-
reactivity with other mutant probes (Supplementary Fig. 2c). We
subsequently validated the de novo mutations in all three cases
using microdissection (Supplementary Fig. 2d) of mutant and
wild-type regions and Sanger sequencing.
Finally, we combined BaseScope with a concurrent in situ
analysis of protein or DNA. Sequential immunohistochemistry
(IHC) for cytokeratin expression and DNA ﬂuorescence in situ
hybridization (FISH) for Chr18q were successful and had no
effect on the tissue morphology or the quality of the BaseScope
signal (Supplementary Fig. 3).
Use of BaseScope 1ZZ probes to detect subclonal architecture.
The spatial distribution of subclonal driver mutations provides
insight into the mechanisms of tumor growth and evolution9, 15.
We sourced archival CRC tumors (n = 8) that had been shown by
the assessment of variant allele frequency (VAF) derived from
NGS to contain possible subclonal driver mutations in KRAS,
BRAF, or PIK3CA. Further samples (n = 3 ‘Ca-in-ad’ tumors) had
been shown to carry subclonal KRAS mutations using the
aforementioned pool of KRAS mutant probes. BaseScope tech-
nology was used to identify subclones, and digital ‘subclonal
maps’ depicting the spatial topology of subclones were generated
from images of 13 lesions from 11 patients (Fig. 3; Supplementary
Fig. 4). Subclones differed greatly in size between tumors (range
3–95% of total tumor), and tiny clonal patches of 10 or fewer cells
were found within ﬁelds of otherwise wild-type cells (Fig. 3a). The
analysis of serial sections permitted 3D reconstruction of clone
shape, which revealed intimate mixing of subclones (Supple-
mentary Movie 1 and Supplementary Fig. 5).
In each of the three ‘Ca-in-ad’ cases, the mutant subclone was
localized to a histologically distinct region. In one case (AB019)
the mutant appeared clonal within the invasive region, with the
non-invasive adenomatous region exclusively KRAS wild-type. In
the two remaining cases (AB016 and AB017), the KRAS mutant
population was at a subclonal frequency within the adenomatous
region, with the carcinoma exclusively KRAS wild-type. The
ﬁnding of KRAS-mutant clones exclusively within precursor
adenomatous regions of a cancerous lesion suggests that KRAS
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Fig. 4 Inference of subclone evolutionary dynamics. Computational modeling predicts the relationship between clone intermixing and clone size, and the
time of clone appearance and selective advantage. Clone mixing level increases to a transient high at intermediate times as the subclone expands, and
decreases as the clone takes over the tumor or is lost (time increases along the columns). The strength of selection experienced by the subclone
determines the speed and maximal extent of subclone mixing (selection increases down the rows). Black dots are empirically measured mixing values in
primary tumors, and are plotted for the parameter values that explain the data with maximum posterior probability (see Methods). The inner panels
(dashed circles) are representative simulation snapshots indicating the expected clonal intermixing. Each panel shows results from 1000 independent
realizations; relative growth ratios of the mutant to wild type are 1, 1.75, 3.0, 8.0 for neutral, weak, intermediate, and strong selection, respectively; the
initial mutant frequency is 0.01 and the ﬁnal tumor size is 104
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mutation status alone could be insufﬁcient to select patients for
EGFR inhibition, and instead the histological location of the
mutation may provide additional predictive information about
drug response.
To characterize the phenotype of the morphologically indis-
tinguishable subclones (‘CRCs’, n = 8, see Supplementary Table 5),
we examined wild-type and mutant regions for expression of Ki67
(proliferation), and CD8 (cytotoxic T lymphocyte inﬁltration,
Supplementary Fig. 6a). We detected cases in which the mutant
subclone displayed distinct molecular phenotypes: in case AB034,
for example, the BRAF V600E mutant subclone displayed
signiﬁcantly elevated proliferation (P = 0.008 by the Mann–Whitney
test, Supplementary Fig. 6b), and in cases AB002 and AB025, the
KRAS G12V mutant subclones displayed signiﬁcant increases in
inﬁltrating cytotoxic T cells (P = 0.02 and P = 0.03 respectively by
the Mann–Whitney test, Supplementary Fig. 6b). There was a weak
association between Ki67 positivity and cytotoxic T cell inﬁltration
(R2 = 0.29, P = 0.033 by the F test, Supplementary Fig. 6c).
We noted highly heterogeneous patterns of subclonal archi-
tecture, with some cases displaying clear clonal boundaries and
others displaying a high level of mixing with wild-type cells
(Fig. 3b). The degree of mixing was quantiﬁed using Shannon’s
entropy (Supplementary Fig. 7a, Supplementary Table 5). Three
samples (AB002, AB028, and AB033) showed particularly high
mixing scores (Supplementary Fig. 7b). The proportion of tumor
occupied by the subclone and the mixing score were not
correlated (P> 0.05 by the F test, Supplementary Fig. 7c).
Subclones arise early or have a large ﬁtness advantage. To
investigate the mechanisms underlying the observed clonal
architectures we computationally modeled the spread of mutant
subclones during tumor growth. Clones expanded by dividing
into vacant space, or pushing neighboring cells to create space.
We simulated scenarios where a driver mutation arose early or
late in tumorigenesis, with various selective advantages compared
to the wild-type. We monitored the mutant frequency and the
degree of clone intermixing (measured by Shannon’s entropy)
over time. As our experimental observations suggested, the
computational model conﬁrmed that mutant frequency and
mixing score have a complex, non-linear relationship (Supple-
mentary Fig. 8a).
In the simulations, neutral mutants rarely underwent large
clonal expansion (Fig. 4, upper panels) whereas strongly selected
mutants could ﬁx (take over) in the tumor (Fig. 4, lower panels).
Irrespective of selection, the level of mixing was initially low when
the new clone was formed, increased to a transient high, and
ﬁnally decreased to a low value as the mutant clone either took
over the population or was lost. The strength of selection
determined the speed of this transient behavior, and the maximal
extent of mixing observed (Fig. 4; Supplementary Fig. 8). The
level of intermixing observed in most primary tumors was
broadly consistent with weak or intermediate selection, or
sampling the tumor at an intermediate time relative to mutation
introduction under strong selection (Fig. 4; Supplementary Fig. 9).
A case with a low mixing score (e.g., AB016) was most likely to be
explained by an early arising mutant with an intermediate ﬁtness
advantage, and conversely a sample with a higher mixing score
(e.g., AB017a1) is more likely to have had a later arising mutant
and with a larger ﬁtness advantage (Supplementary Fig. 8b–e).
We conﬁrmed our ﬁndings in an alternative model, whereby cells
divided without pushing and only ﬁlled neighboring empty spaces
vacated by cell death. The temporal patterns of clone spread and
mixing were qualitatively the same in both formulations of the
model (Supplementary Fig. 10).
Discussion
This manuscript describes the ﬁrst application of the novel 1ZZ
BaseScope in situ hybridization technology to measure the spatial
distribution of point mutations in human archival FFPE samples.
Our analysis shows the very high sensitivity and speciﬁcity of 9
BaseScope probesets, representing common driver mutations in
the genes KRAS (6 probesets), BRAF (1 probeset) and PIK3CA (2
probesets). The sensitivity and speciﬁcity of BaseScope probes
allowed for precise spatial mapping of mutant subclones in
human tumors. These spatial maps reveal the heterogeneity of
clonal mixing patterns in CRC, and we report examples of highly
inﬁltrated, mixed clones, as well as clones with distinct bound-
aries. Computational modeling shows how these spatial data are
indicative of the time of subclone appearance and the relative
ﬁtness of the subclone.
We note that BaseScope detected minor subclones with an
estimated frequency as low as 3%, and these would likely not be
reliably detected by standard ‘bulk’ sequencing. In fact, we report
a number of samples that were previously shown to be KRAS
wild-type by Sanger sequencing, but were shown to contain
validated KRAS mutant subclones by BaseScope. This high sen-
sitivity of subclone detection could have important implications
for the stratiﬁcation of patients for targeted therapy, for example
for EGFR blockade in CRC that requires the tumor to be KRAS
wild-type to be efﬁcacious16. Further work is required to inves-
tigate the clinical utility of the method.
Our results suggest that BaseScope provides a robust technology
for ISMD, a technique that traditionally has been performed using
DNA or RNA in situ PCR with mutation-speciﬁc primers17.
Although they can be effective, in situ PCR approaches such as
rolling circle ampliﬁcation of padlock probes18 are often time
consuming, as they ﬁrst require conversion of mRNA to DNA by
synthesis of a complementary nucleic acid strand prior to hybri-
dization. Furthermore they are technically challenging, as each
probe requires different PCR and hybridization conditions and
extensive optimization. Using BaseScope technology, ISMD can be
performed in approximately 8 h, hybridization conditions are
universal, and minimum assay optimization is required by the
user. Additionally, as BaseScope generates a chromogenic end
product instead of a ﬂuorescent end product, there are no spe-
cialist microscopes required for analysis, and stained slides can be
stored long term. Moreover, we have shown that BaseScope can be
readily combined with sequential IHC or DNA FISH, in order to
concurrently study protein-level or DNA-level alterations in situ.
Recent technology that allows for combining mutation detection
with copy number analysis includes speciﬁc-to-allele PCR–FISH
(STAR-FISH19). In our hands we have found concurrent ISMD
and copy number detection by BaseScope and DNA-FISH offers
improved sensitivity, reliability and reproducibility over STAR-
FISH, as well as a reduced assay time of 24 h (vs. ~40 h).
The BaseScope methodology has a small number of potential
limitations compared with other methods. First, the reliance on
mRNA means that the mutant mRNA must be expressed at a
detectable level in the tissue or cell of interest, and so mutations
within untranscribed regulatory sequences such as promoters will
not be detected by RNA-ISH with BaseScope. Second, some
archival cancer samples may fail owing to poor RNA quality,
although this problem is likely to be restricted to older samples that
have undergone sub-optimal processing. Reassuringly all 51 archi-
val samples (average time since ﬁxation = 6.4 years, range 0–20
years) analyzed in this study were of sufﬁcient quality for analysis
by BaseScope. Third, whilst the method has high speciﬁcity, its
sensitivity for detecting heterozygous mutations is typically ~25%.
In practice, this has minimal effects on the detection of even very
rare subclones, but the method does require some development to
be suitable for true single cell analysis. We note that the BaseScope
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signal is likely to be proportional to the underlying copy-number of
the locus. Finally, some protein-inactivating mutations cause
unstable mRNA–while the speciﬁc mutations will not be detected in
this scenario, we would nonetheless detect reduced or absent
transcript levels by BaseScope using the wild-type control probe.
These limitations can potentially be addressed by a DNA version of
the BaseScope assay in the future.
This manuscript is the ﬁrst to describe the application of point
mutation speciﬁc 1ZZ BaseScope in situ hybridization technol-
ogy. The method provides a robust and efﬁcient approach to
in situ mutation detection. It has broad application in cancer
biology research and the potential for clinical application,
including sensitive identiﬁcation of resistant clones in cancers,
mapping of mutations to benign and malignant components of
mixed tumors and molecular cancer staging.
Methods
Cell lines. Cell lines were obtained from the American Type Culture Collection
(ATCC; www.atcc.org). Frozen aliquots were supplied to AbboMax Inc. (San Jose,
CA) where they were processed into highly consistent and homogenous Cellmax
pellet blocks. A list of cell lines used can be found in Supplementary Table 2.
Patient samples. Formalin-ﬁxed parafﬁn embedded (FFPE) tissue blocks (n = 51,
Supplementary Table 3) were obtained from University College and St Mark’s
Hospitals, London, under multi-center ethical approval (London Stanmore com-
mittee, 11/LO/1613), with all patients giving informed consent. Additional samples
were from the Manchester Cancer Research Centre Biobank (Project
13_NIWR_01); the QUASAR2 trial (ISRCTN45133151, ethical approval REC 09/
H0606/5+5); the COIN trial (ISRCTN; 27286448); and the FOCUS trial (ISRCTN;
79877428, ethical approval 15/EE/0241). The average time since ﬁxation of the
tissue blocks was 6.4 years (range 0–20 years). Samples were examined by at least
two expert histopathologists.
BaseScope assay. BaseScope assays were performed in accordance with guidelines
provided by the supplier (Advanced Cell Diagnostics, Newark, CA). Sections were
taken at 5 μm thickness onto Superfrost plus slides (Fisher Scientiﬁc, Loughbor-
ough, UK) and allowed to dry overnight at room temperature (RT). Sections were
then baked at 60 °C for 1 h before deparafﬁnizing in xylene (2 × 5 min) and ethanol
(2 × 2 min), then drying by baking at 60 °C for 2 min. Pretreat 1 (hydrogen per-
oxide) was applied for 10 min at RT, Pretreat 2 (target retrieval) for 15 min at 100 °
C and Pretreat 3 (protease) for 30 min (tissue sections) or 15 min (cell pellets) at 40
°C, with two rinses in distilled water between pretreatments. BaseScope probes (see
Supplementary Table 1) were then applied for 2 h at 40 °C in a HybEZ oven before
incubation with reagents AMP0 (30 min at 40 °C), AMP1 (15 min at 40 °C), AMP2
(30 min at 40 °C), AMP3 (30 min at 40 °C), AMP4 (15 min at 40 °C), AMP5 (30
min at RT) and AMP6 (15 min at RT). Slides were rinsed with wash buffer (2 × 2
min) between each AMP incubation. Finally slides were incubated with Fast Red
for 10 min at room temperature in the dark. Slides to be used for sequential
staining were kept in PBS at 4 °C overnight before proceeding to the next protocol.
Slides that were not used for further staining were counterstained with Gill’s
hematoxylin before drying for 15 min at 60 °C and mounting in VectaMount
permanent mounting medium (Vector labs, Burlingame, CA).
Immunohistochemistry (IHC). After performing the BaseScope protocol, slides
were blocked in 2% goat serum with 1% bovine serum albumin (BSA) for 1 h at RT.
Primary antibody anti-human cytokeratin (#M3515, Agilent Technologies, Santa
Clara, CA) was applied for 1 h at RT (1:2000 dilution), followed by biotinylated
rabbit anti-mouse secondary antibody (#E0354, Agilent Technologies) for 30 min
at RT (1:400 dilution) then streptavidin-conjugated horseradish peroxidase
(#P0397, Agilent Technologies) for 30 min at RT (1:500 dilution). Slides were
developed in 3,3′-diaminobenzidine (DAB) for 2 min, and counterstained with
Gill’s hematoxylin before drying for 15 min at 60 °C and mounting.
For dual-color IHC, 5 μm serial sections were dewaxed, rehydrated and
immersed in 3% hydrogen peroxide for 20 min to quench endogenous peroxidase
activity. Antigen retrieval was carried out at 95 °C for 20 min in sodium citrate
buffer (pH 6.0). After cooling, sections were incubated with blocking buffer (PBS
supplemented with 2% goat serum and 1% BSA) for 1 h at RT. Primary antibodies
(Ki67, #ab92742, Abcam at 1:2000 dilution) were diluted in blocking buffer and
applied for 1 h at RT. Sections were then incubated with a biotinylated secondary
antibody at RT for 45 min, followed by incubation with streptavidin-biotin
peroxidase solution at RT for 45 min. Visualization of the ﬁrst antibody binding
was carried out using DAB. Slides then underwent a second round of antigen
retrieval, generally at 95 °C for 5 min in sodium citrate buffer (pH 6.0), before
applying the blocking buffer for a further 1 h at RT. The second primary antibody
was then applied (CD8, #7103, Dako at 1:100 dilution), followed by incubation
with a biotinylated secondary antibody at RT for 45 min and incubation with
streptavidin-alkaline phosphatase. Visualization of the second antibody binding
was performed using Fast Red, according to the manufacturer’s instructions
(Abcam, Cambridge, UK). Finally, sections were lightly counterstained using Gill’s
hematoxylin, and allowed to dry before mounting.
For manual scoring of IHC, three representative regions of 100 tumor cells were
considered for the wild-type and mutant regions. For Ki67 staining, the proportion
of nuclei displaying strong positivity was quantiﬁed. For CD8 staining, the number
of positively stained cells inﬁltrating into, or in close proximity to the tumor was
quantiﬁed.
Fluorescent in situ hybridization. After performing the BaseScope protocol,
Fluorescent in situ hybridization (FISH) was performed on the same tissue section
using the FISH accessory kit (Agilent Technologies) according to the manu-
facturer’s guidelines. Sections were incubated overnight at 37 °C with a SureFISH
probe against Chr18q21.2 (#G100219G-8, Agilent Technologies). Nuclei were
counterstained with DAPI, before visualization on the Ariol system (Leica Bio-
systems, Milton Keynes, UK). The BaseScope Fast Red signal is ﬂuorescent in the
red channel, and the FISH probe in the green channel.
Mutation validation by sequencing. Sections of 12 μm thickness were taken serial
to the sections used for the BaseScope assay. For needle macrodissection the sec-
tions were placed onto glass slides, and for laser capture microdissection (LCMD)
onto UV-treated PEN-membrane laser capture slides (Carl Zeiss Microscopy,
Göttingen, Germany). Slides were deparafﬁnized, rehydrated and lightly stained
with methyl green before scraping or LCMD of mutant and wild-type regions of
tumor. DNA was extracted using the QiaAMP DNA micro kit (QIAGEN Ltd,
Manchester, UK) and used for a two-round nested polymerase chain reaction
(PCR) to amplify KRAS exon 1. PCR conditions and primer sequences were. as
previously described20 (First round: forward primer GAGTTTGTATTAAAAGG-
TACTGGTGGA, reverse primer ATCAAAGAATGGTCCTGCAC, 35 cycles 95 °C,
30 s, 60 °C 30 s, 72 °C 30 s. Second round: forward primer TTTGA-
TAGTGTATTAACCTTAT, reverse primer TATTAAAACAAGATTTACCTC,
cycles: 95 °C 30 s, 55 °C 30 s, 72 °C 30 s). Sequencing was performed using BigDye
v3.1 terminator cycle sequencing chemistry on the ABI 3730 DNA analyzer
(Applied Biosystems Inc., Foster City, CA).
2D/3D mapping of subclonal mutations. For 2D mapping, sections were stained
with BaseScope using the relevant 1ZZ mutant probe, and then IHC for cytokeratin
was performed, as described above. Slides were digitized using the Pannoramic
250 scanner (3D Histech, Budapest, Hungary). Wild-type and mutant glands were
manually annotated on each section using Adobe Photoshop CS6, under the
assumption that mutant glands are clonal for the mutation of interest. The sub-
clone proportion was calculated by dividing the pixel count in mutant regions by
the total pixel count in mutant and wild-type regions. Subclones were validated by
an experienced pathologist as being morphologically distinct (‘Ca-in-ads’, n = 5) or
morphologically indistinguishable (‘CRCs’, n = 8). For the 3D map, 120 sections
were taken at 7 μm thickness, then every tenth section was used for the BaseScope
assay with the probe against the KRAS G12A mutation. Scanned data sets were
uploaded and registered in FreeD21 for 3-dimensional reconstruction, as follows.
Serial images (TIFF ﬁle format) were imported into FreeD software v 1.10 image
stack ﬁles. Gland boundaries were drawn manually in each 2D serial image and
connected along the third dimension between adjacent slides. This procedure is
facilitated by simultaneous display of masked gland boundaries during virtual
microscopy in FreeD software. After manual 2D assessment of all virtual tissue
slides of one stack, 3D models can be computed and visualized by interconnection
of the deﬁned masks along the third dimension in FreeD software.
Calculation of Shannon’s entropy. The Shannon entropy metric was used to
quantify spatial heterogeneity of mutant and wild-type populations. Mathematically
the Shannon entropy is deﬁned as S ¼ Pni¼1 pi log2 pi þ 1 pið Þ log2 1 pið Þ
 
=n,
where the tumor image has been divided into n quadrats of the same size and pi is the
frequency of the mutant type in quadrat i. If the mutant and the wild type are fully
mixed, the Shannon’s entropy of the tumor population is 1, whereas if the mutant and
wild type cells are completely spatially separate the Shannon's entropy is 0.
For 2D maps of human CRCs, annotated digitized sections were overlaid with a
grid comprising quadrats of 1300 μm2 (average 96 quadrats per case, range
16–216). Within each quadrat, the percentage of pixels that were yellow (wild-type)
or red (mutant) was calculated using ImageJ22. These measurements were then
used to calculate Shannon’s entropy for each lesion, as described for computer-
generated tumors.
Computational model of subclonal tumor growth. We explored the effects of two
important evolutionary forces on the spatial patterns of mutant and ‘wild-type’
subclones, namely the strength of subclonal selection and the time when the
mutant arises. We modeled the growth of tumor populations and the appearance of
mutants using a spatial stochastic branching process. Cells occupied a simple lattice
with eight nearest neighbors. When a tumor cell divided, one daughter cell was
placed at random in an empty neighboring position and the other daughter cell
remained in the position of the parent cell. If there was no empty position around
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the dividing cell, a random direction was chosen and cells were pushed by one
position in that direction to create space for the new daughter cell. We also con-
sidered an alternative model whereby cells could only divide into a empty neigh-
boring space (i.e. no pushing), and where all cells die randomly at a ﬁxed rate δ.
Neutral evolution was deﬁned as the scenario where the mutant and wild-type cells
had the same division rate, and selection quantiﬁed by the relative increase in the
rate of at which the mutant subclone attempted to divide. We also considered
various arising times (early or late) for the mutant population.
Statistical inference of subclonal dynamics. We employed an Approximate
Bayesian Computation (ABC) approach23. For each CRC we simulated the com-
putational model many times. Each simulation took input parameters that
described the time of subclone arrival and its relative ﬁtness: these parameters
selected from uniform prior distributions, as described in Supplementary Fig. 9.
For each simulation, we calculated how well the simulated data matched the
empirical data, using the Euclidean distance between the observed vs. computed
mutant frequency and mixing score. Simulation instances that produced a Eucli-
dean distance ε< 0.05 were ‘accepted’ into the posterior distribution. The para-
meter values with maximal posterior probabilities were reported for each CRC.
Statistics. Results in the text are reported as mean± 95% conﬁdence intervals
unless stated otherwise. Parametric and non-parametric tests were used as
appropriate, deﬁned in the ﬁgure legends.
Data availability. Data generated and analyzed in this study are available from the
corresponding authors upon reasonable request.
Code availability. Computational code used in this study is available from the
corresponding authors upon reasonable request.
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